These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
580 related articles for article (PubMed ID: 22513796)
1. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic]. Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796 [TBL] [Abstract][Full Text] [Related]
2. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888 [TBL] [Abstract][Full Text] [Related]
3. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279 [TBL] [Abstract][Full Text] [Related]
4. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy. Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876 [TBL] [Abstract][Full Text] [Related]
5. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis. Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099 [TBL] [Abstract][Full Text] [Related]
6. GATA1 mutations in acute leukemia in children with Down syndrome. Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466 [TBL] [Abstract][Full Text] [Related]
7. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804 [TBL] [Abstract][Full Text] [Related]
8. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Roy A; Roberts I; Norton A; Vyas P Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743 [TBL] [Abstract][Full Text] [Related]
10. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433 [TBL] [Abstract][Full Text] [Related]
11. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342 [TBL] [Abstract][Full Text] [Related]
12. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder. Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834 [TBL] [Abstract][Full Text] [Related]
13. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131 [TBL] [Abstract][Full Text] [Related]
14. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children. Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042 [TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Langebrake C; Creutzig U; Reinhardt D Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703 [TBL] [Abstract][Full Text] [Related]
16. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651 [TBL] [Abstract][Full Text] [Related]
17. Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease. Moritake H; Yamada A; Kimoto Y; Sawa D; Shimonodan H; Nunoi H Am J Hematol; 2012 Apr; 87(4):447-50. PubMed ID: 22389016 [No Abstract] [Full Text] [Related]
18. Presentation of Acute Megakaryoblastic Leukemia Associated with a GATA-1 Mutation Mimicking the Eruption of Transient Myeloproliferative Disorder. Boos MD; Wine Lee L; Freedman JL; Novoa RA; Chu EY; Perman MJ Pediatr Dermatol; 2015; 32(5):e204-7. PubMed ID: 26205501 [TBL] [Abstract][Full Text] [Related]
19. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547 [TBL] [Abstract][Full Text] [Related]
20. Are GATA1 mutations occurring at random in Down syndrome transient leukemia? Satgé D Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]